Consort Medical

Pharmaceutical manufacturer, Aesica, is now the market leader in the production of the active pharmaceutical ingredient, flurbiprofen, a drug used to treat the pain and inflammation associated with Arthritis.

The company has achieved its market leading position as a result of continuous process improvement, investment in facilities and its ability to respond quickly, providing tailored solutions to specific market requirements. Furthermore, the company has combined its heritage of quality, innovation, customer service and reliability with a competitive pricing strategy, enabling it to secure new business in Turkey and across emerging markets in Asia.

Kevin Cook, Managing Director, Active Pharmaceutical Ingredients business unit, Aesica says: “There is a trend within the pharmaceutical industry for mature medicines to grow within emerging markets and this is something which we have witnessed with flurbiprofen. The generics market has experienced significant and rapid growth across Asia and our ability to react swiftly and efficiently to supply these markets has been a crucial factor in our success. Moreover, the competitive offering, added value and enhanced service provision we are able to offer has firmly established Aesica as leader in this marketplace.

“As market demands continue to grow, we will continue to expand our flurbiprofen manufacturing capacity to ensure Aesica remains competitive within the global marketplace. This clearly demonstrates our drive to further increase our market share and remain the leader in the flurbiprofen market.”

Aesica manufactures flurbiprofen at its Cramlington site in the North East of England where the drug has been produced for over twenty years, after the purpose built facility was originally developed by Boots in 1983. Aesica has manufactured flurbiprofen for the last seven years and in that time has doubled the volume of the API manufactured at the site.

Aesica is a leading full-service provider of contract research, development and manufacturing services for Formulated Products and Active Pharmaceutical Ingredients. The company develops long-term strategic partnerships with its clients, responds quickly and effectively to market demand and develops tailored solutions for specific requirements.